key: cord-0700596-cozf7kkc
authors: Ahmed Syed, Mohamed; Sameer Al Nuaimi, Ahmed; Abdulla A/Qotba, Hamda
title: Risk of SARS-CoV2 by vaccination status and population characteristics in Qatar
date: 2022-05-12
journal: Clin Infect Pract
DOI: 10.1016/j.clinpr.2022.100148
sha: 475f3dea76fdefad47c82a192cc89fd3f1fc1573
doc_id: 700596
cord_uid: cozf7kkc

nan

The duration of protection offered by SARS-CoV2 has important implications on booster vaccination programs. Additional vaccination doses are reasonable for individuals who demonstrate need. The findings of this study provide evidence and a rationale for prioritisaion BNT162b2 or mRNA-1273 vaccines based on specific population characteristics.

Results of this study show that the BNT162b2 or mRNA-1273 vaccine are highly effective two weeks after the second dose. However, it consistently declines over time. Anecdotal evidence suggests advanced age as a factor to priotise booster doses, findings of this study suggest that older age (≥ 60) have a lower risk of infection compared with 12-19 year olds after controlling for the comorbidities.

The study provides important insights on the influence of comorbidities on the risk of SARS-CoV2 infection -Diabetes, obesity and arthritis are associated with over 22 % higher risk. This is a strength of the study. Such findings have previous not been report due to non-availability data on comorbidities. While the study includes the entire population along with a long follow up duration and most importantly the study design, a limitation was a small representation of the ≥ 60 (5.6%) age group.

The findings of this study provide evidence on whom and when vaccinations are likely to be most advantageous. In the context of the on-going vaccination supply constraints, surge in omicron variant infections and other factors, where necessary, countries are urged to identify and prioritise higher risk populations for initial and booster dose vaccination programs.

Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis

Waning Immunity after the BNT162b2 Vaccine in Israel

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

The authors would like to thank Jazeel Abdulmajeed and Muhammad Kawsar Harun for his support in extracting data from PHCC's electronic medical records.

The study presented a minimal risk of harm to its subjects, and the data collected for it were anonymised. None of the subjects' personal information was available to the research team.Overall, the study was conducted with integrity according to generally accepted ethical principles and was reviewed and approved under the exempt review category by the PHCC's Research Sub-Committee (PHCC/DCR/2021/05/035).

We declare no competing interests.

This study was funded by PHCC. The funders had no role in the design, analysis, interpretation, or writing. The authors had full access to all the data had final responsibility for the decision to submit for publication.